Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Weak Q3 For Biocon, All Eyes On Biosimilars Approval Flow

Executive Summary

Biocon reported a decline in profits for the third quarter but recent regulatory wins and advancements for its biosimilars portfolio could potentially bring an uptick in growth going forward.


Related Content

Riding The Next Wave Of Biosimilars: Sandoz To Link Up With India's Biocon
More Cheer For Biocon-Mylan As Brazil Clears Biosimilar Trastuzumab
Keeping Track: FDA Hands Out Complete Responses, Expedited Pathway Designations
Biocon/Fujifilm Enter Lantus Biosimilar Fray In Japan


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts